Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
AMBUSH study is a multicenter randomized, controlled, open-label clinical trial (PROBE (Prospective Randomized Open Blinded End-point) type).
The main objective of AMBUSH study is to assess the effect of therapeutic management guided by pulmonary ultrasound and the assessment of the inferior vena cava in patients with heart failure seen in an ambulatory (outpatient) setting on a mixed clinical-biological endpoint (including variations of natriuretic peptides - NtProBNP) at 30 days.
Secondary objectives are:
A. To assess the effect of therapeutic management guided by pulmonary ultrasound and inferior vena cava assessment on the risk of cardiovascular death and hospitalization for heart failure at 30 days.
B. Describe the proportion of ultrasound congestion (pulmonary and inferior vena cava data) in patients free from clinical congestion at baseline in the intervention group and in all patients at D30 visit.
C. Evaluate the association of ultrasound congestion (pulmonary and inferior vena cava assessment) with serum concentrations of natriuretic peptides at baseline and D30 visit.
D. Evaluate the association of variations in ultrasound congestion (pulmonary and evaluation of the inferior vena cava) and variations in natriuretic peptides between baseline and D30 visit.
E. Compare the proportion of ultrasound and clinical congestion in patients in the intervention group and in the control group at baseline and on D30 visit.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Interventional group | Experimental | The heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava |
|
| Control group | Other | Usual care (i.e. without ultrasound guidance) will be provided. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava. | Procedure | An ultrasound (lung and inferior vena cava) will be performed and the heart failure treatments will be guided by the results of the lung ultrasound and the evaluation of the inferior vena cava. The choice of congestion treatment modalities to be implemented is left to the investigators' discretion, in accordance with European practice guidelines. |
| Measure | Description | Time Frame |
|---|---|---|
| Death within 30 days (composite endpoint) | The primary endpoint will rank patients from worst to most favourable outcome during the trial. It will be a hierarchical composite of events as described by Felker in 2010 (PMID 20841546). | Within 30 days |
| Hospitalization for heart failure within 30 days (composite endpoint) | The primary endpoint will rank patients from worst to most favourable outcome during the trial. It will be a hierarchical composite of events as described by Felker in 2010 (PMID 20841546). | Within 30 days |
| Changes in N-terminal pro b-type natriuretic peptide (NtProBNP) between randomization and D30 (composite endpoint) | The primary endpoint will rank patients from worst to most favourable outcome during the trial. It will be a hierarchical composite of events as described by Felker in 2010 (PMID 20841546). | Between randomization and Day 30 |
| Measure | Description | Time Frame |
|---|---|---|
| Cardiovascular death | Within the combined outcome of CV death or hospitalization for heart failure. Outcomes will be adjudicated blinded from randomization arm | Within 30 days |
| Ultrasound pulmonary congestion defined ≥3 B-lines on two intercostal spaces bilaterally (8-point method) and systemic congestion defined as an inferior vena cava diameter 21 mm or greater and/or a low variation during the respiratory cycle |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Nicolas GIRERD, MD,PhD | Contact | +33 3 83 15 74 96 | +333 | n.girerd@chru-nancy.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Besançon | Not yet recruiting | Besançon | 25030 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Usual care without ultrasound guidance | Procedure | Usual care (i.e. without ultrasound guidance) |
|
| At baseline in the intervention group and in all patients at Day 30 post inclusion |
| Circulating levels of natriuretic peptides (NtProBNP) | At baseline and Day 30 |
| Changes in natriuretic peptides (NtProBNP) | Between baseline and Day 30. |
| Ultrasound congestion defined as in B / and clinical congestion evaluated according to the EVEREST and ASCEND scores | At baseline in the intervention group and in all patients at the Day 30. |
| CH de Mulhouse | Not yet recruiting | Mulhouse | 68070 | France |
|
| CHRU de Reims | Not yet recruiting | Reims | 51092 | France |
|
| CHR de Metz | Not yet recruiting | Thionville | 57126 | France |
|
| CHRU de Nancy | Recruiting | Vandœuvre-lès-Nancy | 54500 | France |
|
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided